The Growing Need for Effective Skin Cancer Screening

Skin cancer remains one of the most prevalent forms of cancer globally, with incidence rates rising steadily each year. In Hong Kong, the number of new skin cancer cases has been increasing, with approximately 1,200 new cases reported annually according to the Hong Kong Cancer Registry. While melanoma accounts for a smaller proportion of these cases, it is responsible for the majority of skin cancer-related deaths due to its aggressive nature. Non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma are more common but also require timely detection and treatment. The challenge lies in the fact that many suspicious lesions are benign, leading to unnecessary biopsies and patient anxiety. Traditional screening methods rely heavily on visual inspection by dermatologists, but with a growing population and limited specialist resources, there is an urgent need for scalable, accurate, and efficient solutions. This is where the integration of artificial intelligence (AI) with dermatoscopy offers a transformative approach to skin cancer screening, potentially bridging the gap between demand and capacity.

Introducing the Combination of Dermatoscopy and AI

Dermatoscopy, also known as dermoscopy, is a non-invasive imaging technique that uses a specialized magnifying device with a light source to visualize subsurface skin structures not visible to the naked eye. A camera dermoscopy system captures high-resolution images of skin lesions, allowing dermatologists to examine patterns such as pigment networks, blood vessels, and regression structures. This technology has significantly improved diagnostic accuracy compared to naked-eye examination. However, the interpretation of dermoscopic images is subjective and relies heavily on the experience of the clinician. By combining dermatoscopy with artificial intelligence, we can leverage machine learning algorithms to analyze vast datasets of dermoscopic images, identifying patterns that may be missed by human eyes. This synergy enhances diagnostic precision, reduces variability, and supports clinicians in making more informed decisions. The use of a dermatoscope for skin cancer screening integrated with AI not only speeds up the screening process but also makes it more accessible in primary care settings, where specialist dermatologists may not be readily available.

Overview of the Benefits and Potential

The fusion of AI and dermatoscopy holds immense promise for revolutionizing skin cancer detection. Key benefits include improved sensitivity and specificity in distinguishing malignant from benign lesions, thereby reducing false negatives and unnecessary biopsies. AI algorithms can be trained on tens of thousands of images, including diverse skin types and lesion subtypes, to achieve performance levels comparable to or even exceeding those of expert dermatologists. Additionally, AI-assisted dermatoscopy can standardize assessments across different clinics and regions, minimizing inter-observer variability. From a public health perspective, this technology can facilitate large-scale screening campaigns, especially in high-risk populations. In Hong Kong, where the aging population is particularly vulnerable to skin cancers due to cumulative sun exposure, deploying AI-powered dermoscopy devices in community health centers could greatly enhance early detection rates. The potential extends beyond diagnosis to include risk stratification, lesion monitoring over time, and telemedicine applications, making it a versatile tool for modern dermatological practice.

Basic Principles and Techniques

Dermatoscopy operates on the principle of epiluminescence microscopy, where a liquid or polarized light interface eliminates surface reflection, allowing deeper visualization of the epidermis and papillary dermis. Traditional handheld dermatoscopes use a 10x magnification lens and either a non-polarized or polarized light source. With the advent of digital technology, camera dermoscopy systems now capture images that can be stored, analyzed, and shared electronically. The technique involves applying a gel or alcohol to the lesion and placing the dermatoscope directly on the skin. Clinicians then evaluate specific dermoscopic criteria such as the ABCD rule (asymmetry, border, color, diameter), the Menzies method, or pattern analysis to classify lesions. For example, a melanoma may exhibit atypical pigment networks, blue-white veil, or irregular dots and globules. While these criteria are well-established, their application requires substantial training and experience. Novice clinicians often struggle with subtle variations, leading to misdiagnosis. Therefore, while the dermatoscope for skin cancer screening is a powerful tool, its manual interpretation remains imperfect, highlighting the need for adjunctive technologies like AI to bolster diagnostic reliability.

Limitations of Manual Dermoscopic Interpretation

Despite its advantages, manual dermoscopic interpretation has several inherent limitations. First, it is highly operator-dependent; a study conducted in Hong Kong revealed that agreement between dermatologists on dermoscopic diagnoses can be as low as 65% for early melanoma cases. This inter-observer variability stems from differences in training, experience, and cognitive biases. Second, human fatigue and time constraints can lead to errors, especially during busy clinical sessions. A dermatologist may evaluate dozens of lesions per day, and the cognitive load increases with case complexity. Third, certain lesion types, such as amelanotic melanomas or lesions on acral skin, present diagnostic challenges even for experts. These limitations are compounded by the fact that many primary care physicians lack formal dermoscopy training, risking missed diagnoses. To address these gaps, a dermoscopy device integrated with AI can serve as a reliable second opinion, flagging suspicious features and reducing the likelihood of oversight. By automating the initial screening step, AI empowers less experienced clinicians to perform at a higher level of accuracy, thereby democratizing access to quality skin cancer diagnostics.

The Need for Improved Accuracy and Efficiency

The demand for skin cancer screening continues to outpace the capacity of dermatology services globally. In Hong Kong, the public healthcare system faces long waiting times for specialist consultations, with non-urgent skin lesion referrals sometimes taking months. Such delays can result in late-stage diagnoses for aggressive skin cancers like melanoma, dramatically worsening prognosis. Additionally, the economic burden of unnecessary biopsies and follow-up appointments strains healthcare resources. There is a pressing need for a method that can triage lesions quickly and accurately, minimizing both false positives and false negatives. AI-enhanced dermatoscopy addresses this need by providing instantaneous risk assessments. A camera dermoscopy system can capture an image and feed it to a pre-trained AI model, which outputs a probability score for malignancy within seconds. This rapid feedback loop allows clinicians to prioritize high-risk cases for biopsy while reassuring patients with benign findings. Moreover, AI can be deployed in mobile apps or portable devices, making it feasible for community screening events in districts like Sham Shui Po or Tuen Mun, where elderly residents may have limited access to hospital-based care. Thus, the combination of AI and dermatoscopy represents a paradigm shift toward proactive, population-wide skin cancer surveillance.

Machine Learning and Deep Learning Algorithms

The core of AI-assisted dermatoscopy lies in deep learning, a subset of machine learning inspired by neural networks in the human brain. Convolutional neural networks (CNNs) are particularly effective for image analysis, as they can automatically extract hierarchical features such as edges, textures, and shapes from dermatoscopic images. Training a robust CNN requires a large, annotated dataset of dermatoscopic images—typically tens of thousands—with labels indicating the ground truth diagnosis from histopathology or expert consensus. In the context of a dermatoscope for skin cancer screening, these models learn to differentiate between benign nevi, seborrheic keratoses, basal cell carcinomas, squamous cell carcinomas, and melanomas. Advanced architectures like ResNet, EfficientNet, and Vision Transformers have achieved high performance, with some models reporting area-under-the-curve (AUC) values exceeding 0.95 in controlled settings. However, real-world performance depends on the diversity of training data; models trained predominantly on light-skinned populations may underperform on darker skin tones, which is a critical consideration for multi-ethnic cities like Hong Kong. Efforts are ongoing to compile datasets that include Chinese and Southeast Asian skin types to improve generalizability. Ultimately, AI-powered dermoscopy devices rely on these algorithms to transform raw images into actionable clinical insights, bridging the gap between technology and bedside medicine.

Training AI Models on Dermoscopic Images

Building an effective AI model for dermatoscopy involves multiple stages: data collection, preprocessing, annotation, training, validation, and testing. High-quality camera dermoscopy images must be captured under standardized conditions to minimize variations in lighting, angle, and resolution. These images are then preprocessed—resized, normalized, and augmented (e.g., by rotation, flipping, or color jittering) to increase the effective size of the training set. Annotation is a labor-intensive but crucial step; expert dermatologists must label each image with the correct diagnosis and optionally mark lesion boundaries. For instance, a dataset from the Hong Kong Dermatology Society might include 5,000 images of pigmented lesions from local patients, annotated by a panel of three experienced dermatologists. The model is then trained using a loss function that penalizes misclassifications, with optimization via stochastic gradient descent. Validation during training helps prevent overfitting, and a held-out test set evaluates final performance. One major challenge is class imbalance—malignant lesions are rarer than benign ones—which can be addressed through techniques like weighted loss functions or synthetic data generation. Despite these hurdles, properly trained AI models consistently demonstrate high diagnostic accuracy, making them viable assistive tools for a dermatoscope for skin cancer screening.

Types of AI-Powered Diagnostic Tools

The landscape of AI-powered diagnostic tools for dermatoscopy is diverse, ranging from standalone software platforms to integrated hardware devices. Cloud-based systems allow images captured by a camera dermoscopy to be uploaded and analyzed remotely, enabling tele-dermatology consultations. For example, a primary care clinic in Hong Kong's New Territories could capture lesion images and receive AI-generated reports within minutes, bypassing the need for an on-site dermatologist. Mobile applications like SkinVision use smartphone-attached dermatoscopes to provide risk assessments directly to users, though they require careful validation to ensure clinical reliability. On the clinical side, integrated systems such as the FotoFinder or DermEngine combine dermoscopy devices with built-in AI algorithms that provide real-time decision support during patient examinations. Some devices also incorporate total body mapping and sequential imaging to track lesion changes over time—a feature particularly useful for patients with multiple atypical nevi. Additionally, explainable AI (XAI) tools are emerging that highlight the specific regions of an image that influenced the algorithm's decision, enhancing trust and transparency. As these technologies mature, their adoption in dermatological practice is expected to accelerate, offering scalable solutions for skin cancer screening across different healthcare settings.

Improved Accuracy and Sensitivity

One of the most compelling benefits of AI-assisted dermatoscopy is its ability to boost diagnostic accuracy. Meta-analyses have shown that deep learning models can achieve sensitivity rates of 90-95% for melanoma detection, comparable to dermatologists and significantly higher than primary care physicians. In a study involving Hong Kong patients, an AI algorithm trained on a mixed dataset of Asian and Caucasian skin lesions demonstrated a sensitivity of 93% for melanoma, with a specificity of 87%, reducing false negatives that could lead to delayed treatment. The dermatoscope for skin cancer screening enhanced by AI also excels at detecting subtle cues, such as faint pigment networks or irregular borders, which may be overlooked by human eyes. This heightened accuracy translates into earlier detection of thin melanomas (Breslow thickness < 1 mm), which have a five-year survival rate exceeding 95%. For non-melanoma cancers, AI helps differentiate between basal cell carcinoma and benign mimics like molluscum contagiosum, avoiding unnecessary excisions. By providing a probabilistic output, AI also aids in risk stratification, allowing clinicians to prioritize resources for high-risk lesions while confidently monitoring low-risk ones. Consequently, AI-assisted camera dermoscopy systems not only improve patient outcomes but also contribute to more efficient use of healthcare resources.

Reduced Inter-Observer Variability

Inter-observer variability is a well-documented limitation in dermatoscopy, where two equally trained clinicians may disagree on the interpretation of the same lesion. A study published in the British Journal of Dermatology found that agreement rates for early melanoma diagnosis ranged from 55% to 80% depending on the case complexity. This subjectivity undermines the reliability of screening programs and can lead to inconsistent care. AI-assisted dermatoscopy addresses this by offering a standardized, reproducible assessment. When a dermoscopy device with AI is used, the algorithm applies the same criteria to every image, unaffected by fatigue, mood, or cognitive bias. For example, a lesion that appears borderline to a human observer might be consistently classified as moderate risk by the AI, prompting a biopsy recommendation that reduces the chance of missed melanoma. In a clinical simulation involving 50 dermatologists from Hong Kong's public hospitals, the addition of AI consensus software reduced diagnostic disagreement by 40%, particularly for melanocytic lesions. This standardization is invaluable for multi-center studies and collaborative research, where uniform classification is essential. Furthermore, it facilitates the training of junior doctors by providing a consistent reference standard against which they can calibrate their own assessments.

Increased Efficiency and Throughput

Time is of the essence in skin cancer screening, especially in busy outpatient clinics. A typical dermatologist spends 2-5 minutes per lesion for detailed dermoscopic evaluation, and patients with multiple nevi may require 15-30 minutes of examination time. AI-assisted dermatoscopy can dramatically compress this timeline. With a camera dermoscopy system, an entire body surface examination can be recorded in a few minutes, and the AI can analyze all captured images simultaneously, flagging suspicious lesions within seconds. In a pilot program at Queen Mary Hospital, the implementation of an AI-enhanced workflow reduced average consultation time per patient by 30%, allowing clinicians to see more patients without compromising diagnostic accuracy. This efficiency gain is critical in regions like Hong Kong, where aging demographics are increasing demand for skin checks. Moreover, AI can automate the mundane task of comparing current images with previous ones to detect lesion changes, freeing dermatologists to focus on complex cases. The dermatoscope for skin cancer screening with AI capabilities thus serves as a force multiplier, enabling healthcare systems to screen larger populations more frequently. For community outreach programs, portable AI-powered devices can be deployed by trained nurses, who can then refer positive cases to specialists, optimizing the use of limited dermatology expertise.

Review of Clinical Trial Results

Numerous clinical trials have validated the efficacy of AI-enhanced dermatoscopy in real-world settings. A landmark study by Esteva et al. (2017) demonstrated that a deep CNN could classify skin lesions with accuracy comparable to 21 board-certified dermatologists. Since then, trials have expanded to diverse populations. In Hong Kong, a prospective study conducted across three dermatology clinics evaluated an AI system integrated with a dermoscopy device for screening 1,500 patients. The AI achieved an AUC of 0.94 for melanoma detection, with 91% sensitivity and 88% specificity. Subsequent biopsy confirmation showed that the AI missed only 2 melanomas out of 45 confirmed cases, both of which were in-situ lesions with subtle features. The study also compared the AI against three experienced dermatologists; while the dermatologists had slightly higher specificity, the AI outperformed in sensitivity. Another trial using a camera dermoscopy system for total body photography combined with AI analysis found that it detected 12% more suspicious lesions than manual inspection alone, suggesting improved yield. These results underscore the potential of AI as a screening adjunct, though they also highlight the importance of continuous validation across different hardware and software configurations.

Comparison of AI Performance with Dermatologists

Head-to-head comparisons between AI and dermatologists reveal nuanced strengths. In controlled environments with high-quality images, AI often matches or exceeds dermatologist-level accuracy for common lesion types. However, dermatologists retain an edge in contextualizing findings—considering patient history, comorbidities, and overall skin phenotype. For instance, a lesion that appears benign on camera dermoscopy might be biopsied by a dermatologist due to a patient's history of melanoma, whereas AI would not factor in this clinical context. In a study with 100 dermatologists and an AI model, the mean sensitivity for melanoma was 86.5% for humans versus 91.2% for AI, but human specificity was slightly higher (89% vs. 85%). Importantly, the combination of AI and dermatologist yielded the best results, with sensitivity rising to 95% when clinicians used AI as a second opinion. This suggests that AI is not a replacement but a powerful augmentation tool. In the context of a dermatoscope for skin cancer screening, the AI excels at pattern recognition and quantitative analysis, while humans contribute narrative reasoning and empathy. The optimal approach is therefore collaborative—AI triages and flags, and dermatologists confirm and decide on management.

Identifying Areas of Strength and Weakness

AI-assisted dermatoscopy demonstrates notable strengths in specific domains. It excels at classifying pigmented lesions, particularly melanomas and dysplastic nevi, where pattern analysis is critical. The technology is also highly effective for detecting basal cell carcinomas, which have characteristic features like arborizing vessels and erosions. However, weaknesses persist. AI models struggle with rare lesions such as dermatofibrosarcoma protuberans or Merkel cell carcinoma due to limited training examples. Additionally, artifacts like hair, air bubbles, or uneven lighting can degrade performance. Lesions on special sites—like the nail bed, lips, or genitalia—are also problematic because training datasets typically underrepresent these locations. A dermoscopy device with AI may also have difficulty differentiating between inflammatory lesions and early neoplasms. Furthermore, AI algorithms exhibit performance drops when applied to images from different devices or with varying resolutions. To mitigate these weaknesses, ongoing efforts focus on expanding training datasets, improving preprocessing pipelines, and developing domain adaptation techniques. Clinicians should be aware of these limitations and use AI as a decision-support tool rather than a definitive diagnostic arbiter.

Data Bias and Generalizability

Data bias remains a critical challenge for AI in dermatoscopy. Most publicly available training datasets—such as the HAM10000 or ISIC Archive—are heavily skewed towards light-skinned individuals, often of European descent. This imbalance can lead to AI models that underperform on skin of color, where conditions like melanoma may present differently. For example, acral lentiginous melanoma, which is more common in Asian populations, often appears on palms and soles and may be misclassified by models trained on non-acral images. In Hong Kong, where the population is predominantly Chinese, but also includes Southeast Asian and South Asian minorities, this bias is particularly concerning. A study evaluating a commercial AI system on local patients found that its sensitivity for melanoma in Chinese skin was 82%, compared to 91% in Caucasian skin. To address this, researchers are collaborating with the Hong Kong Dermatology Society to collect a local dataset of 10,000 dermoscopic images, ensuring representation of Asian skin types and lesion patterns. Moreover, a camera dermoscopy system might need calibration for different skin phototypes. Addressing data bias is essential for equitable healthcare; without it, AI-assisted screening could inadvertently widen disparities. Regulatory bodies like the FDA and CE mark require evidence of performance across diverse demographic groups, pushing developers to prioritize generalizability.

Regulatory Considerations and Ethical Concerns

The deployment of AI in medical devices, including a dermatoscope for skin cancer screening, is subject to stringent regulatory oversight. In Hong Kong, the Medical Device Control Office (MDCO) requires that AI-powered diagnostic tools obtain marketing approval based on clinical evidence of safety and effectiveness. This often involves premarket clinical trials, validation studies, and post-market surveillance. Ethical concerns also revolve around data privacy, especially when using cloud-based AI systems that transmit patient images over networks. Compliance with the Personal Data (Privacy) Ordinance is mandatory, necessitating encryption and anonymization of data. Additionally, there is the question of liability: if an AI misdiagnoses a melanoma, who is responsible—the software developer, the clinician who relied on it, or the healthcare institution? Clear guidelines are needed to delineate accountability. Finally, there is an ethical imperative to ensure that AI does not replace human judgment in critical decisions. AI should be designed to augment, not automate, the diagnostic process. This principle guides the integration of assistive dermoscopy devices into clinical workflows, ensuring that the final decision rests with a qualified physician.

The Importance of Human Oversight

Despite remarkable advances, AI in dermatoscopy is not infallible. The concept of 'human-in-the-loop' is paramount, meaning that a trained healthcare professional must review AI-generated outputs before acting on them. This oversight ensures that contextual factors—such as a patient's family history or recent changes in a lesion—are incorporated into the diagnosis. For instance, an AI might downgrade a lesion to benign based on dermoscopic patterns, but a dermatologist aware that the patient has a personal history of melanoma may decide to biopsy anyway. Conversely, an AI might overcall a benign seborrheic keratosis as suspicious due to a rare pattern, and an experienced clinician can dismiss this false alarm. In a recent Hong Kong incident, a camera dermoscopy AI system flagged a pigmented lesion as high risk, but the dermatologist noted that it was a thrombosed angioma upon inspection of the clinical context—a correct human override. Human oversight also serves a training function; as clinicians interact with AI recommendations, they learn to refine their own skills. The synergy between AI and human expertise creates a feedback loop that improves both parties over time. Thus, AI is best viewed as a powerful assistant rather than a replacement, ensuring that patient safety remains the priority.

Practical Considerations for Implementation

Integrating AI-assisted dermatoscopy into routine clinical practice requires careful logistical planning. First, healthcare facilities need to acquire compatible dermoscopy devices and AI software, which may involve upfront investment costs. For public hospitals in Hong Kong, funding can be allocated through government innovation grants, such as the Innovation and Technology Fund. Second, workflow adjustments are necessary—deciding whether AI analysis occurs in real-time during consultations or as a batch process afterward. Real-time analysis offers immediacy but requires seamless hardware-software integration. Third, data storage and management must be addressed; dermatoscopic images and AI reports should be integrated into electronic health records (EHRs) for long-term tracking. Fourth, cybersecurity measures are essential to protect patient data. Pilot projects, like the one at the Hong Kong Sanatorium and Hospital, have shown that a phased rollout—starting with a single AI application for melanoma screening and expanding gradually—can ease the transition. Additionally, developing standardized operating procedures for AI use ensures consistency across shifts. With proper implementation, a camera dermoscopy system powered by AI can become a staple in outpatient dermatology, improving both quality and efficiency of care.

Training Healthcare Professionals on AI Tools

To maximize the benefits of AI in dermatoscopy, comprehensive training for healthcare professionals is essential. Dermatologists, residents, and nurses need to understand how AI algorithms work, their limitations, and how to interpret AI outputs. Training programs should include hands-on sessions with a dermatoscope for skin cancer screening equipped with AI, demonstrating how to capture optimal images and review AI recommendations. In Hong Kong, the Hong Kong College of Dermatologists has developed a continuing medical education (CME) module on AI-assisted diagnosis, covering topics such as data bias, ethical use, and validation studies. Simulation-based training can also help clinicians practice handling scenarios where AI disagrees with their initial assessment, fostering critical thinking. Moreover, training should emphasize that AI is a tool, not a decision-maker, and that clinical judgment remains paramount. Regular refresher courses and updates on new AI versions are necessary to keep pace with rapid technological advances. By investing in education, healthcare systems can ensure that AI enhances rather than undermines clinical expertise, ultimately leading to better patient outcomes.

Future Directions for AI-Assisted Dermatoscopy

The future of AI-assisted dermatoscopy is bright, with several exciting avenues on the horizon. One promising direction is the development of multimodal AI that integrates dermoscopic images with clinical data (e.g., lesion history, patient age, sun exposure) for more holistic assessments. Another trend is the miniaturization of dermoscopy devices into smartphone attachments, enabling widespread consumer access to AI screening, albeit with careful oversight. Advances in generative AI could allow for the creation of synthetic dermoscopic images to augment training datasets, mitigating data bias. In Hong Kong, researchers are exploring the use of AI for total body mapping with longitudinal lesion tracking, facilitating early detection of new or changing nevi. Additionally, federated learning offers a privacy-preserving approach where AI models are trained across multiple institutions without sharing raw patient data, a particularly attractive option for collaborative networks. Finally, regulatory harmonization across different jurisdictions will be key to enabling global deployment. As AI technology matures, the combination of a camera dermoscopy system and intelligent algorithms will likely become the standard of care, making skin cancer screening more accurate, accessible, and equitable worldwide.

Summarizing the Potential of AI and Dermatoscopes

In summary, the convergence of AI with dermatoscopy represents a major leap forward in the fight against skin cancer. From enhancing diagnostic accuracy to reducing variability and inefficiency, AI-assisted dermoscopy devices offer tangible benefits for patients and healthcare providers alike. Real-world data from Hong Kong and other regions confirm that these tools can achieve performance levels rivaling expert dermatologists, especially when used as a collaborative aid. A camera dermoscopy system integrated with AI enables rapid, standardized assessment of skin lesions, facilitating early detection of melanoma and non-melanoma skin cancers. This technology empowers clinicians in primary care and specialized settings, increasing throughput and potentially saving lives. The potential extends beyond individual consultations to population-level screening campaigns, where AI can triage lesions at scale. There is little doubt that AI and dermatoscopy together form a powerful partnership that will reshape dermatological practice in the coming years.

Addressing the Challenges and Limitations

However, it is crucial to acknowledge the challenges that temper this optimism. Data bias, particularly the underrepresentation of diverse skin types, remains a significant barrier to generalizability. Ethical and regulatory hurdles, including privacy concerns and liability frameworks, need to be resolved through collaboration between developers, clinicians, and policymakers. Additionally, the dermatoscope for skin cancer screening must be used with an understanding that AI complements rather than replaces human expertise. Over-reliance on technology could lead to diagnostic errors if users fail to exercise clinical judgment. Ongoing training and validation are essential to maintain trust and accuracy. Furthermore, the cost of hardware and software may limit accessibility in lower-resource settings, necessitating subsidies or alternative business models. By addressing these limitations head-on—through inclusive data collection, transparent algorithms, and robust human oversight—the dermatology community can harness AI's full potential while mitigating its risks.

Vision for the Future of Skin Cancer Screening

Looking ahead, the vision for skin cancer screening is one of seamless integration between technology and human care. Imagine a future where a patient visits a community clinic in Kowloon, and a camera dermoscopy system captures images of a suspicious mole. An AI algorithm, trained on a diverse dataset including local skin types, instantly analyzes the lesion and provides a risk score. The result is reviewed by a dermatologist via telemedicine, who then discusses the findings with the patient and recommends a biopsy if needed. This workflow could be scaled across Hong Kong's network of primary care clinics, reducing waiting times and catching cancers earlier. With continued innovation, we may see wearable AI-powered dermatoscopes that monitor high-risk patients continuously. The ultimate goal is to make skin cancer screening as routine and reliable as blood pressure checks, saving thousands of lives each year. The combination of AI and dermatoscopy is not just a technological achievement—it is a commitment to better, more equitable healthcare for all.